Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 6/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | CLK3 | P49761 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833169 | 0.88 | DYRK1A (0.44) | DYRK1AGSK3BFGFR3KDRCLK2 | |
| SCHEMBL6803727 | 0.83 | DYRK1A (0.46) | DYRK1AGSK3BCLK2CLK3GRM5 | |
| SCHEMBL6804288 | 0.82 | LCK (0.45) | KDRABL1KITGRM5BRAF | |
| SCHEMBL6804372 | 0.81 | DYRK1A (0.45) | DYRK1AGSK3BFGFR3KDRCLK2 | |
| SCHEMBL6756890 | 0.78 | DYRK1A (0.44) | DYRK1AGSK3BKDRCLK2CLK3 | |
| SCHEMBL6804275 | 0.75 | MAPK14 (0.48) | KDRABL1KITDDR2BRAF | |
| SCHEMBL7120271 | 0.75 | DYRK1A (0.51) | DYRK1AGSK3BFGFR3KDRCLK2 | |
| SCHEMBL6808765 | 0.74 | SMN1; SMN2 (0.43) | KDRKITGRM5RXFP1 | |
| SCHEMBL6760435 | 0.73 | DYRK1A (0.45) | DYRK1AGSK3BKDRCLK2CLK3 | |
| SCHEMBL6757933 | 0.73 | SCN4A (0.42) | DYRK1AKITGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266774-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| US-6770667-B1 | N-((IMIDAZOLYL)-PHENYL)-FLUORENE-1-CARBOXAMIDE DERIVATIVES; 5-HYDROXYTRYPTAMINE (5-HT) ANTAGONISTS; PSYCHOLOGICAL, NERVOUS SYSTEM, EATING, BRAIN AND SLEEP DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| EP-1216240-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001025229-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266774-A1 | Amide compounds | TPH1, HTR1A, HTR5A | DYRK1A 2942/4885GSK3B 2135/4885FGFR3 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.